Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations
Year: 2026
Type: article
Source: Journal of Clinical Oncology
DOI: 10.1200/jco-26-00280
Authors: Lieke Mous, Stelly Ballet, Sylvain Dureau, Camille Benoist, Eleonore Frouin, Victor Renault, Laura Kirton, Peter Peneder, Nina Jehanno, Anja L. Frei, Stéphanie Reynaud, Eve Lapouble, Anne-Sophie Plissonnier, Marie-Emmanuelle Legrier, Ellen Blanc, Aurélie Guinot, Jennifer Anderton, Piers Gaunt, Abigail Evans, Sandra J. Strauss, Manuela Krumbholz, Markus Metzler, Elizabeth A. Roundhill, Susan A. Burchill, Samuel Abbou, Sarah Winter, Martin G. McCabe, Nathalie Gaspar, Birgit Geoerger, Gudrun Schleiermacher, Eleni M. Tomazou, Nadège Corradini, Valerie Laurence, Bernadette Brennan, Perrine Marec-Berard, Olivier Delattre, Gaelle Pierron, Didier Surdez
Institutions: University of Zurich, Université Paris Sciences et Lettres, Institut Curie, Cancer Research UK Clinical Trials Unit, St. Anna Children's Cancer Research Institute, Centre Léon Bérard, University College London, National Health Service, University College London Hospitals NHS Foundation Trust, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, St James's University Hospital, Université Paris-Saclay, Institut Gustave Roussy, The Christie NHS Foundation Trust, Translational Research Institute, Inserm, Translational Research in Oncology, Medical University of Vienna, Royal Manchester Children's Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7225271381